Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia

NCT02687425 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions

DRUG: Pioglitazone
DRUG: imatinib mesylate

Sponsor

Meng Li